Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Giving chemotherapy before a donor umbilical cord blood stem cell transplant helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining tumor cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methylprednisolone after the transplant may stop this from happening.
PURPOSE: This phase I trial is studying the side effects of busulfan, melphalan, and antithymocyte globulin followed by umbilical cord blood transplant in treating young patients with refractory or relapsed malignant solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Unspecified Childhood Solid Tumor, Protocol Specific |
Biological: anti-thymocyte globulin Biological: graft-versus-tumor induction therapy Biological: sargramostim Drug: busulfan Drug: cyclosporine Drug: melphalan Drug: methylprednisolone Other: flow cytometry Other: immunologic technique Other: laboratory biomarker analysis Procedure: allogeneic hematopoietic stem cell transplantation Procedure: umbilical cord blood transplantation |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors |
- Safety [ Designated as safety issue: Yes ]
- Incidence of graft-versus-host disease [ Designated as safety issue: No ]
- Donor/host chimerism status [ Designated as safety issue: No ]
- Immune function post-transplant [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2004 |
OBJECTIVES:
- Examine the impact of the use of killer cell immunoglobulin-like receptor (KIR)-mismatched umbilical cord blood as a source of hematopoietic stem cells, after busulfan, melphalan, and anti-thymocyte globulin in pediatric patients with relapsed or refractory solid tumors.
- Determine the toxicity of this regimen, in terms of incidence of grade 3-4 acute graft-versus-host disease, donor/host chimerism, and cellular immunity against tumor cell lines, in these patients.
OUTLINE:
- Transplantation: Patients receive busulfan orally or IV every 6 hours on days -8 to -5, anti-thymocyte globulin IV over 6 hours on days -4 to -1, and melphalan IV over 15-20 minutes on days -4 to -2. Patients undergo allogeneic umbilical cord blood stem cell infusion on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
- Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV over 1 hour or orally twice daily on days -1 to 180 and methylprednisolone IV or orally once or twice daily on days 5 - 49.
Blood samples are collected periodically for immunophenotyping and flow cytometric analysis (including interferon gamma and other TH1 and TH2 cytokines).
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | up to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosis of malignant solid tumor
Relapsed or refractory disease
- No isolated local recurrence of disease (in the site of the primary tumor) > 1 year after completing therapy
- No brain tumors or brain metastases
Unrelated cord blood donor available
May be HLA 6/6 matched (HLA-A, -B, -DR) OR mismatched for 1, 2, or 3 of these HLA loci, but must be mismatched for HLA-C group as indicated by their following killer cell immunoglobulin-like receptor (KIR) group specificity:
KIR2DL1
- Cw 2
- Cw 0307
- Cw 4, 5, 6
- Cw 0707, 0709
- Cw 1204, 1205
- All other Cw 15 alleles
- Cw 1602
- Cw 17
- Cw 18
KIR2DL2
- Cw 1
- All other Cw 3 alleles
- All other Cw 7 alleles
- Cw 8
- Cw 1202, 1203, 1206
- Cw 1301
- Cw 1402, 1403
- Cw 1507
- Cw 1601, 1604
- Cord blood specimen must have ≥ 1 x 10^7 nucleated cells/kg patient ideal body weight
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-2 OR Lansky PS 70-100%
- Cardiac ejection fraction ≥ 50%
- Creatinine clearance ≥ 50%
- Bilirubin ≤ 3.0 mg/dL
- DLCO ≥ 70% OR O_2 saturation ≥ 95% on room air
PRIOR CONCURRENT THERAPY:
- Prior autologous stem cell transplantation allowed
Contacts and Locations| United States, Pennsylvania | |
| Penn State Cancer Institute at Milton S. Hershey Medical Center | |
| Hershey, Pennsylvania, United States, 17033-0850 | |
| Study Chair: | Kenneth G. Lucas, MD | Milton S. Hershey Medical Center |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00436761 History of Changes |
| Other Study ID Numbers: | CDR0000529361, PSCI-18589 |
| Study First Received: | February 15, 2007 |
| Last Updated: | September 18, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
unspecified childhood solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Neoplasms Antilymphocyte Serum Busulfan Cyclosporins Cyclosporine Melphalan Methylprednisolone Hemisuccinate Prednisolone Methylprednisolone acetate Prednisolone acetate Methylprednisolone Prednisolone hemisuccinate Prednisolone phosphate Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Myeloablative Agonists Enzyme Inhibitors Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Anti-Inflammatory Agents Antiemetics |
ClinicalTrials.gov processed this record on May 16, 2013